- Home
- XFOR vs BGSF Comparison
XFOR vs BGSF Comparison
Compare XFOR & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- BGSF
- Stock Information
- Founded
- XFOR 2014
- BGSF 2007
- Country
- XFOR United States
- BGSF United States
- Employees
- XFOR N/A
- BGSF N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- BGSF Professional Services
- Sector
- XFOR Health Care
- BGSF Consumer Discretionary
- Exchange
- XFOR Nasdaq
- BGSF Nasdaq
- Market Cap
- XFOR 84.3M
- BGSF 70.1M
- IPO Year
- XFOR N/A
- BGSF N/A
- Fundamental
- Price
- XFOR $3.81
- BGSF $3.39
- Analyst Decision
- XFOR Strong Buy
- BGSF Strong Buy
- Analyst Count
- XFOR 3
- BGSF 1
- Target Price
- XFOR $34.17
- BGSF $9.00
- AVG Volume (30 Days)
- XFOR 1.4M
- BGSF 178.3K
- Earning Date
- XFOR 11-12-2025
- BGSF 11-05-2025
- Dividend Yield
- XFOR N/A
- BGSF 58.31%
- EPS Growth
- XFOR N/A
- BGSF N/A
- EPS
- XFOR N/A
- BGSF N/A
- Revenue
- XFOR $32,774,000.00
- BGSF $266,615,000.00
- Revenue This Year
- XFOR $1,307.51
- BGSF N/A
- Revenue Next Year
- XFOR N/A
- BGSF $3.14
- P/E Ratio
- XFOR N/A
- BGSF N/A
- Revenue Growth
- XFOR 5721.31
- BGSF 28.60
- 52 Week Low
- XFOR $1.35
- BGSF $2.91
- 52 Week High
- XFOR $26.83
- BGSF $8.22
- Technical
- Relative Strength Index (RSI)
- XFOR 62.18
- BGSF 27.92
- Support Level
- XFOR $2.96
- BGSF $3.44
- Resistance Level
- XFOR $4.54
- BGSF $3.67
- Average True Range (ATR)
- XFOR 0.27
- BGSF 0.16
- MACD
- XFOR 0.07
- BGSF 0.02
- Stochastic Oscillator
- XFOR 55.75
- BGSF 3.33
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About BGSF BGSF Inc.
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.